Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary

PharmacoEconomics

Volumn 32, Issue 10, 2014, Pages 937-942

  Gauld, Robin ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; EDITORIAL; GOVERNMENT; HEALTH CARE; HEALTH CARE ORGANIZATION; NEW ZEALAND; DRUG CONTROL; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; HISTORY; HUMAN; PHARMACOECONOMICS;

PRESCRIPTION DRUG;

DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; FINANCING, GOVERNMENT; GOVERNMENT AGENCIES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEW ZEALAND; PRESCRIPTION DRUGS;

EID: 84916928508     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0178-2     Document Type: Editorial

References (29)

1. Ragupathy R, Aaltonen K, Tordoff J, Norris P, Reith D. A three-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics. 2012;30(11):1051–65.
2. Gauld R. Revolving doors: New Zealand’s health reforms: the Saga continues. Wellington: Institute of Policy Studies and Health Services Research Centre; 2009.
3. Gauld R. New Zealand’s post-2008 health system reforms: toward re-centralization of organizational arrangements. Health Policy. 2012;106:110–3.
4. Clark H. Pharmaceutical costs and regulation: from the Minister’s desk. In: Davis P, editor. For health or profit? Medicine, the pharmaceutical industry, and the state in New Zealand. Auckland: Oxford University Press; 1992. p. 53–74.
5. Wilson JQ. Bureaucracy: what government agencies do and why they do it. New York: Basic Books; 1989.
6. Pharmaceutical Management Agency. Pharmac’s decision criteria: consultation document. Wellington: Pharmaceutical Management Agency; 2013.
7. Grocott R. Applying programme budgeting marginal analysis in the health sector: 12 years of experience. Expert Rev Pharmacoecon Outcomes Res. 2009;9(2):181–7.
8. Grocott R, Metcalfe S, Alexander P, Werner R. Assessing the value for money of pharmaceuticals in New Zealand: Pharmac’s approach to cost-utility analysis. N Z Med J. 2013;126(1378):60–73.
9. Goldacre B. Bad pharma: how drug companies mislead doctors and harm patients. London: Fourth Estate; 2012.
10. Milne R, Wonder M. Response to Pharmac on access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124(1347):91–3.
11. Rasiah D, Edwards R, Crampton P. Funding community medicines by exception: a descriptive epidemiological study from New Zealand. N Z Med J. 2012;125(1350):21–9.
12. Coyle G. How does the operation of Pharmac’s ‘Community Exceptional Circumstances’ policy align with the distributive justice principles of fairness and equity as described by John Rawls and Amartya Sen? Auckland University of Technology PhD thesis; 2012.
13. Manning J. Exceptional circumstances schemes and the social factors exclusion in healthcare rationing. Oxford Univ Commonwealth Law J. 2013;13(1):75–114.
14. Tordoff J, Norris P, Reith D. ‘Price management’ and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand. Value Health. 2008;11(7):1214–26.
15. OECD. Health at a Glance 2013. Paris: OECD; 2013.
16. Pharmaceutical Management Agency. Pharmaceutical Management Agency. Annual Review 2013. Wellington: Pharmaceutical Management Agency; 2013.
17. OECD. OECD Health Data. Paris: OECD; 2013.
18. The US health system in perspective: a comparison of twelve industrialized nations. New York: Commonwealth Fund; 2011.
19. Cobiac L. Pharmac looks great value for money: an Australian perspective. N Z Med J. 2012;125(1358):82–3.
20. Duckett S, Breadon P, Ginnivan L, Venkararaman P. Australia’s bad drug deal: high pharmaceutical prices. Melbourne: Grattan Institute; 2013.
21. Fenton E. Making fair funding decisions for high cost cancer care: the case of herceptin in New Zealand. Public Health Ethics. 2010;3(2):137–46.
22. Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124(1346):12–28.
23. Moodie P, Metcalfe S, Poynton M. Do pharmaceutical score cards give us the answers we seek? N Z Med J. 2011;124(1346):69–74.
24. Cumming J, Mays N, Daube J. How New Zealand has contained expenditure on drugs. BMJ. 2010;340(c2441):1224–7.
25. Begg E, Sidwell A, Gardiner S, Nicholls G, Scott R. The sorry saga of the statins in New Zealand: pharmacopolitics versus patient care. N Z Med J. 2003;116(1170):U360.
26. Ellis CJ, White H. Pharmac and the statin debacle. N Z Med J. 2006;119(1236).
27. Moodie P, Dougherty S, Metcalfe S. Pharmac and statins: getting the best population health gains. N Z Med J. 2006;119(1238):1–3.
28. Gleeson D, Lopert R, Reid P. How the Trans Pacific Partnership Agreement could undermine Pharmac and threaten access to affordable medicines and health equity in New Zealand. Health Policy. 2013;112:227–33.
29. Davis P. Tough but fair? The active management of the New Zealand Drug Benefits Scheme by an independent crown agency. Aust Health Rev. 2004;28(2):171–81.